Our live Investing Matters Podcast Special which took place at the Master Investor Show discussing 'How undervalued is the UK stock market?', has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Oxford Biomedica wins new agreement for LentiVector platform

Wed, 05th Jan 2022 08:54

(Alliance News) - Oxford Biomedica PLC announced on Wednesday it has signed a license and multi-year supply agreement with Philadelphia-based biotechnology company Cabaletta Bio Inc for its LentiVector platform.

The Oxford-based gene and cell therapy company said the financial arrangements of the license and supply agreement are "in line with comparable deals the group has previously secured".

The agreement grants Cabaletta Bio with a non-exclusive license to the company's LentiVector platform, which will be used by Cabaletta Bio in its chimeric autoantibody receptor T programme focused on DSG3-CAART.

DSG3-CAART is being developed to treat mucosal pemphigus vulgaris, a blistering skin disease that affects mucous membranes.

Oxford Biomedica's LentiVector platform is a lentiviral-based gene delivery system that enables the development of gene and cell-based medicines. Lentivirus is a type of virus that causes chronic and deadly illnesses such as AIDS.

Shares in Oxford Biomedica were up 0.5% at 1,216.00 pence each on Wednesday morning in London.

By Heather Rydings; heatherrydings@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

Related Shares

More News
5 Mar 2024 17:09

EARNINGS AND TRADING: Harland & Wolff wins major Falklands contract

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reporte...

5 Mar 2024 16:22

Oxford Biomedica shares rise on post-acquisition guidance

(Sharecast News) - Shares in cell and gene therapy specialist Oxford Biomedica were jumping on Tuesday afternoon, after the company updated the market...

5 Mar 2024 08:57

LONDON BROKER RATINGS: Barclays cuts Bank of Ireland to 'equal weight'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

5 Feb 2024 11:34

EnSilica hires new chief financial officer from Oxford Biomedica

(Alliance News) - EnSilica PLC on Monday said it has appointed a new chief financial officer, who will join the company and board in May.

29 Jan 2024 12:35

IN BRIEF: Institut Merieux ups stake in Oxford BioMedica toward 10%

Oxford BioMedica PLC - Oxfordshire, England-based gene and cell therapy - Completes purchase of ABL Europe SAS from Institut Merieux SA, cementing the...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.